yes, there should be info shared (if not a ques asked) about production scale up as its a large ongoing expense.
AT1's own production level however is slightly irrelevant in current Ag RDT potential and ongoing publicity. At present, all of AT1's contracts are for HIV tests (Galileo device) + for Ab tests (Pascal device in AccBio n Ng Bio RDTs). There should be plenty of spare production for any these as the orders are lesser qty.
AT1's Ag RDTs are rebranded Access Bio nasal tests....who have been scaling up US production for last 8mths+. They should already be producing 30m+ Ag RDTs per mth (low estimate from past Carestart orders ann'd for US market alone).
AT1 should have no Ag RDT supply issues for AU or India or any market that it can break into for its sales.
